At Achillion, we are driven to transform the lives of patients and families affected by diseases of the complement system, an integral part of the innate immune system. Scientific and clinical evidence has implicated the complement system, and specifically the complement Alternative Pathway (AP), in numerous devastating diseases and conditions. Our principal focus at Achillion is to advance our clinical-stage portfolio of orally administered factor D inhibitors into late-stage development and potential commercialization for patients with devastating disorders of the AP. Source
No articles found.
We are a clinical stage biopharmaceutical company leveraging our two proprietary t...
We are a clinical stage biopharmaceutical compa...
iCAD, Inc. an industry-leading provider of advanced image analysis, workflow solut...
iCAD, Inc. an industry-leading provider of adva...
LoveBug Probiotics brings customers an award-winning range of probiotic supplement...
LoveBug Probiotics brings customers an award-wi...
Moderna is advancing messenger RNA (mRNA) science to create a new class of transfo...
Moderna is advancing messenger RNA (mRNA) scien...
Join the National Investor Network and get the latest information with your interests in mind.